SYSTEMATIC REVIEW article
Front. Med.
Sec. Nuclear Medicine
This article is part of the Research TopicExpert Opinions & Viewpoints in Nuclear MedicineView all 3 articles
The prognostic role of Maximum Tumor Dissemination (Dmax) derived by PET/CT in oncological diseases: a systematic review
Provisionally accepted
- 1University Institute for Positron Emission Tomography, Skopje, North Macedonia, skopje, North Macedonia
- 2Institute of Oncology Research, Bellinzona, Switzerland
- 3Spitalul Universitar de Urgenta Militar Central Dr Carol Davila, Bucharest, Romania
- 4University of Brescia, Brescia, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background/Objectives: Maximum tumor dissemination (Dmax) measured by positron-emission tomography/computed tomography (PET/CT) is a semiquantitative parameter recently introduced with potential prognostic role in several oncological diseases. It is defined as a three-dimensional feature that represents the maximal distance between the two farthest hypermetabolic PET lesions. The aim of our systematic review is to investigate the effective role of Dmax in the management of oncological patients. Methods: The current systematic review was carried out following a preset protocol, and the "Preferred Reporting Items for a Systematic Review and Meta-Analysis" served as a guideline for its development. A comprehensive search of the PubMed/MEDLINE, Embase and Cochrane library databases was conducted until August 2025. Results: A total of 37 studies were included in our research. Lymphoma was the most frequent cancer investigated, followed by prostate cancer, lung cancer and breast cancer. Despite their heterogeneity, most studies showed a significant prognostic role of Dmax in predicting overall survival (OS) and progression free survival (PFS). The combination of Dmax with other PET features, especially MTV, seemed to be useful to stratify patients risk of relapse and/or death. Conclusions: Despite several limitations affecting this analysis, especially related to the heterogeneity of the studies included, PET/CT seems to have a prognostic impact in several oncological diseases, especially in lymphoma. However, few methodological issues still need to be solved before we can implement Dmax in clinical practice.
Keywords: Dmax, FDG, Lymphoma, Nuclear Medicine, PET, PET/CT
Received: 16 Oct 2025; Accepted: 04 Dec 2025.
Copyright: © 2025 Tasevski, Treglia, Marin, Bertagna and Albano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Domenico Albano
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.